KRYS Earnings Date: Nov 2, 2026 (Estimated) — Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is KRYS's next earnings date?
Krystal Biotech, Inc. (KRYS) is expected to report Q3 2026 earnings on Monday, November 2, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $1.79 on revenue of $125.8M.
How did KRYS do in its last earnings report?
In its most recent report on Aug 3, 2026 (Q2 2026), Krystal Biotech, Inc. posted EPS of $1.79 versus the $1.89 estimate, a miss of 5.3%. Revenue was $119.2M against a $122.8M estimate. The stock's 1-day post-earnings move was -8.4%.
How much does KRYS stock move after earnings?
KRYS beat EPS estimates in 5 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.0% (up or down) in the day after earnings.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-03 | Q2 2026 | 1.89 | 1.79 | -5.29% | $119.2M | ❌ Miss | -8.37% | -4.30% | +5.35% |
| 2026-05-04 | Q1 2026 | 1.43 | 1.83 | +27.97% | $116.4M | ✅ Beat | +7.86% | +14.91% | +10.21% |
| 2026-02-17 | Q4 2025 | 1.61 | 1.70 | +5.59% | $107.1M | ✅ Beat | +4.12% | -0.67% | -7.28% |
| 2025-11-03 | Q3 2025 | 1.12 | 2.66 | +137.50% | $97.8M | ✅ Beat | +0.17% | +0.21% | +8.89% |
| 2025-08-04 | Q2 2025 | 1.29 | 1.29 | +0.00% | $96.0M | ➖ Inline | -14.04% | -11.67% | -5.08% |
| 2025-05-06 | Q1 2025 | 1.52 | 1.20 | -21.05% | $88.2M | ❌ Miss | -14.06% | -14.09% | -18.65% |
| 2025-02-19 | Q4 2024 | 1.29 | 1.52 | +17.83% | $91.1M | ✅ Beat | +12.43% | +15.58% | +20.74% |
| 2024-11-04 | Q3 2024 | 0.90 | 0.91 | +1.11% | $83.8M | ✅ Beat | -3.14% | +13.16% | +5.43% |
Showing last 8 quarters.
Revenue by segment & region
By region
Q2 FY26 · $119.2M total
| Segment | Share | Revenue | YoY | Q2 FY26 |
|---|---|---|---|---|
| UNITED STATES | 76.9% | $91.6M | — | $91.6M |
| Europe | 16.2% | $19.3M | — | $19.3M |
| JAPAN | 7.0% | $8.3M | — | $8.3M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.